No Data
Abbisko Cayman Unit's Solid Tumor Drug Gets US FDA Approval for IND Application
He Yu-B (02256.HK): The innovative PRMT5*MTA inhibitor ABSK131 IND application has been approved by the usa FDA.
Grayscale on December 3rd: HoYu-B (02256.HK) announced that the highly selective small molecule PRMT5*MTA inhibitor ABSK131 has received FDA's IND approval. This approval is for conducting Phase I clinical trials in advanced solid tumor patients. The trial is titled "A Phase I, first-in-human, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABSK131 in patients with advanced/metastatic solid tumors." The study population mainly consists of patients with loss of the cancer suppressor gene MTAP. Approximately 15% of human solid tumors lack the cancer suppressor gene.
Express News | Abbisko Cayman Ltd - U.S. FDA Ind Clearance for Absk131
Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug
Hoi-B (02256.HK): The first dose of the II phase clinical trial of oral PD-L1 small molecule inhibitor ABSK043 combined with FGFR2/3 small molecule inhibitor ABSK061 for the treatment of solid tumors was administered to a gastric cancer patient.
On November 22, 2023, Gelonghui announced that He Yu-B (02256.HK) completed the administration to the first gastric cancer patient in the "open-label multicenter phase II clinical study (protocol number: ABSK061-201) evaluating the safety and efficacy of ABSK061 and ABSK043 alone or in combination with chemotherapy in patients with FGFR2/3 altered metastatic/unresectable solid tumors."
HK stocks anomaly | Hoyo-B (02256) now up more than 4%. The results of the Phase III clinical trial of Pembrolizumab are announced. If Merck chooses to exercise the option, it will enhance the company's performance.
Glory-B (02256) rose more than 8% intraday, as of the time of publication, it increased by 4.15%, closing at 4.27 Hong Kong dollars, with a turnover of 6.335 million Hong Kong dollars.
No Data
No Data